NTC has in pipeline several drugs in Ophthalmology, Paediatrics and Gastroenterology.
One of NTC primary goals is to develop new products designed to contribute to the fight against Antibiotic Resistance (ABR), following with the most recent guidelines recognized by the scientific and medical organizations worldwide.

In particular, in Ophthalmology and in Paediatrics, a major NTC endpoint is to make available to patients novel therapeutic solutions designed for the treatment and/or the prevention of infections with a clear focus on the rationalization of the use of antibiotics.

In Gastroenterology, the NTC aim is to bring to market products that might improve patient compliance: a special effort was dedicated to enhancing the patient experience when preparing for a colonoscopy through the creation of a palatable, easy-to take and quick onset drug.